Metforlip/Metforlip SR Special Precautions

Metforlip: Metformin is known to be substantially excreted by the kidney, and the risk of Metformin accumulation and lactic acidosis is increased with the degree of impairment of renal function. Thus, patients with serum creatinine levels above the upper limit of normal should not receive Metformin. In patients with advanced age, Metformin should be carefully titrated to establish minimum dose for adequate glycemic control, because aging is associated with reduced renal function. Metformin therapy should be temporarily suspended for any surgical procedure and should not be restarted until the patient's oral intake has resumed and renal function has been evaluated as normal. During concomitant therapy with sulfonylurea, blood glucose should be monitored. Metformin & insulin therapy should be carried out in hospital until the correct ratio of the two drugs has been established.
Metforlip SR: Monitoring renal function regularly is advised in all patients taking Metformin. Therapy should be stopped 2-3 days before surgery and clinical investigations such as intravenous urology, angiography and reinstated only after control of renal function has been regained. Patients receiving continuous therapy should have an annual estimation of vitamin B12 levels. During concomitant therapy with sulfonylurea, blood glucose should be monitored. Metformin & insulin therapy should be carried out in hospital until the correct ratio of the two drugs has been established.